Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
June 01, 2024 08:00 ET
|
Kymera Therapeutics, Inc.
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement...
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
May 31, 2024 12:00 ET
|
Alberta Cancer Foundation
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
Local startup Oncobiotix
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
May 31, 2024 08:00 ET
|
Novartis Pharma AG
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs....
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
May 31, 2024 07:30 ET
|
Adaptive Biotechnologies
SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
May 31, 2024 07:00 ET
|
atai Life Sciences
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis
May 30, 2024 08:00 ET
|
Olink Proteomics AB
Landmark study using the Olink Explore platform identifes proteins in the blood that may provide a 7-year warning for various cancers.
Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma
May 30, 2024 07:00 ET
|
Elevar Therapeutics
Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment for uHCCFinal analysis...
L’Université de Reims Champagne-Ardenne (URCA) choisit Eviden pour son nouveau supercalculateur Roméo, intégrant la technologie NVIDIA, et destiné aux communautés de recherche scientifique du Grand-Est
May 30, 2024 06:00 ET
|
Atos International
Communiqué de presse L’Université de Reims Champagne-Ardenne (URCA) choisit Eviden pour son nouveau supercalculateur Roméo, intégrant la technologie NVIDIA, et destiné aux communautés de...
The University of Reims Champagne-Ardenne (URCA) chooses Eviden for its new ROMEO supercomputer, powered by NVIDIA, and designed for Grand Est scientific research communities
May 30, 2024 06:00 ET
|
Atos International
Press release The University of Reims Champagne-Ardenne (URCA) chooses Eviden for its new ROMEO supercomputer, powered by NVIDIA, and designed for...
Anocca AB and Shinobi Therapeutics Announce Strategic Partnership to Develop Allogeneic TCR-T Cell Therapies in Oncology
May 30, 2024 06:00 ET
|
Anocca AB
SÖDERTÄLJE, Sweden and SAN FRANCISCO and KYOTO, Japan, May 30, 2024 (GLOBE NEWSWIRE) -- Anocca AB (Anocca), a leading T-cell receptor-engineered T-cell (TCR-T) therapeutics company, and...